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AGNETIC RESONANCE IMAGING OF HUNTINGTON’S DISEASE:
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bstract—The known genetic mutation causing Huntington’s
isease (HD) makes this disease an important model to study
inks between gene and brain function. An autosomal domi-
ant family history and the availability of a sensitive and
pecific genetic test allow pre-clinical diagnosis many years
efore the onset of any typical clinical signs. This review
ummarizes recent magnetic resonance imaging (MRI)–b-
sed findings in HD with a focus on the requirements if
maging is to be used in treatment trials. Despite its mono-
enetic cause, HD presents with a range of clinical manifes-
ations, not explained by variation in the number of CAG
epeats in the affected population. Neuroimaging studies
ave revealed a complex pattern of structural and functional
hanges affecting widespread cortical and subcortical re-
ions far beyond the confines of the striatal degeneration
hat characterizes this disorder. Besides striatal dysfunction,
unctional imaging studies have reported a variable pattern of
ncreased and decreased activation in cortical regions in
oth pre-clinical and clinically manifest HD-gene mutation
arriers. Beyond regional brain activation changes, evidence
rom functional and diffusion-weighted MRI further suggests
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416.
-mail address: stefan.kloeppel@uniklinik-freiburg.de (S. Klöppel).
bbreviations: AD, Alzheimer’s disease; BOLD, blood-oxygenation
evel dependent; BSI, brain boundary shift integral; CSF, cerebrospinal
uid; DWI, diffusion-weighted imaging; FA, fractional anisotropy; fMRI,
unctional magnetic resonance imaging; FWHM, full-width at half-maxi-
um; GM, grey matter; HD, Huntington’s disease; ICA, independent
omponent analysis; MRI, magnetic resonance imaging; PD, Parkinson’s
isease; PSC, presymptomatic gene carriers; ROI, region of interest;s
CN, temporally coherent networks; TIV, total intracranial volume; VBM,
oxel-based morphometry; WM, white matter.
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Open access under CC BY liceisrupted connectivity between corticocortical and corticos-
riatal areas. However, substantial inconsistencies with re-
pect to structural and functional changes have been re-
orted in a number of studies. Possible explanations include
ethodological factors and differences in study samples.
here may also be biological explanations but these are
oorly characterized and understood at present. Additional
nsights into this phenotypic variability derived from study of
ouse models are presented to explore this phenomenon.
© 2009 IBRO. Published by Elsevier Ltd.
ey words: Huntington’s disease, imaging, basal ganglia,
ubject stratification.
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untington’s disease (HD) is an autosomal dominant neuro-
egenerative disorder with an average age of onset around
0 years and an incidence of 4–10 per 100,000 in the
nited States and Western European countries. It is caused
y a CAG repeat expansion in the gene encoding the protein
untingtin. The availability of a sensitive and specific genetic
est allows pre-clinical diagnosis, many years before the on-
Open access under CC BY license.et of unequivocal motor signs (Walker, 2007).
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219206Within the present overview, we plan to update and ex-
end recent review articles on imaging in HD (Henley et al.,
005; Montoya et al., 2006; Aylward, 2007; Bohanna et al.,
008). We will focus on the use of imaging for clinical thera-
eutic trials and will consider factors that need to be taken
nto account when designing them. In a disease like HD,
here is a need to follow the effects of neuro-degeneration in
ndividuals over time to evaluate degeneration-modifying
reatments. Optimally, monitoring should occur in both the
re-clinical and clinically manifest stages of the disease. Cur-
ently, it is difficult to monitor the progression of neuro-degener-
tion in asymptomatic individuals using clinical or neuropsycho-
ogical testing. Ideally, imagingwould be used to stratify subjects
y degree of caudate atrophy, well before the onset of unequiv-
cal clinical signs. Such stratification would potentially make it
ossible to stage subjects into more homogeneous popula-
ions and to assess the effects of treatments on different
tages in the evolution of this neuro-degenerative disorder.
We will focus mainly on T1-weighted structural imaging
ethods since treatment trials are likely to include multiple
linical centers where technical requirements for diffusion
eighted imaging (DWI) or functional magnetic resonance
maging (fMRI) studies are often not readily available and
otentially more difficult to standardize. There are however
rst encouraging data from DWI (Landman et al., 2007;
akana et al., 2007) and fMRI studies (Bosnell et al.,
008) preparing for multi-center and multimodality strate-
ies and applications in the future.
We start by briefly outlining structural imaging methods,
ncluding some caveats in their application. In the second
ection, we highlight current evidence for structural imaging
bnormalities in HD, associations between atrophy visualized in
ivo and clinical performance, and discuss imaging evidence for
he stratification of HD subjects based on, e.g. the number of
AG repeats, clinical phenotype, or pattern of cognitive impair-
ent. We consider this critical for the optimal design of clinical
rials, as clinically defined characteristics may be associated
ith differential rates and distribution of degeneration. The
hird and fourth section reviews fMRI and DWI data with a
ocus on their usefulness for the characterization of individual
ubjects before entering treatment trials. The fifth section
ummarizes data from imaging studies in HD mouse models
nd illustrates how such data aid in the stratification of sub-
ects and in the interpretation of imaging findings.
Beyond issues related to imaging-based criteria for
ubject inclusion in trials, the next step will be to find
ensitive methods to detect possible effects of proposed
reatments. The concluding section therefore provides an
pdate on the ongoing discussion about imaging-derived
easures as biomarkers of disease progression.
This selective review will restrict itself to magnetic res-
nance imaging (MRI). Imaging of cerebral blood flow and
lucose metabolism has been the focus of another recent
eview (Ma and Eidelberg, 2007).
STRUCTURAL IMAGING METHODS
tructural MRI analyses in HD have yielded inconsistent
ndings (see 2nd section). Discrepancies are likely to be cue to methodological differences in the analysis tech-
iques applied, as well as true heterogeneity in the cohorts
tudied. In this section we summarize some of the image
nalysis techniques currently used to investigate neurode-
eneration in HD.
Structural MRI investigations typically fall into two cate-
ories: (1) hypothesis-driven region of interest (ROI) studies on
athologically-affected structures, and (2) more exploratory un-
iased whole-brain analyses, requiring no a priori assumptions.
OI analyses
he current gold-standard measurement technique for ROI
olumetry is manual segmentation. This involves an expert
ater tracing around the outline of the structure on every
slice” of theMR image. Manual segmentation has been used
xtensively to investigate atrophy in the caudate, putamen,
rontal lobe, and globus pallidus (Harris et al., 1992; Aylward
t al., 1997, 1998; Aylward et al., 2000; Rosas et al., 2001,
003; Fennema-Notestine et al., 2004; Paulsen et al.,
006b). However, this approach is extremely time consum-
ng, and results are subject to inter- and intra-rater variability.
As an alternative to manual-outlining algorithms, sev-
ral fully automated segmentation and anatomical labeling
echniques have been developed (Khan et al., 2008).
hese techniques are likely to be used more frequently in
uture studies if they are shown to be reliable. Both man-
al- and automated-ROI-based analyses are limited by
ifficulties in accurately and reliably outlining small struc-
ures, especially if the structure is complex and contains
oorly defined boundaries.
hole-brain analyses
he most elementary whole-brain analysis is visual as-
essment of the MR images by a radiologist. However,
uantification via visual rating scales is crude and subject
o inter- and intra-rater variation.
The brain boundary shift (BSI) integral is a semi-auto-
ated technique for measuring whole-brain volume change
rom serial MRI (Freeborough and Fox, 1997), and can be
sed to capture the full extent of diffuse cerebral volume loss
n HD (Henley et al., 2006). The volume of atrophy is mea-
ured directly from the difference in brain boundaries of reg-
stered scan pairs, thereby, reducing the impact of segmenter
ariability on results since the quantification does not rely on
anual segmentation per se. One limitation of the BSI is its
nability to localize change to specific tissues. In addition,
here is a possibility that degeneration in one structure might
e accompanied by an enlargement in another which may
ot result in changes at the brain boundary.
Voxel-based morphometry (VBM) (Ashburner and Fris-
on, 2000) and cortical thickness analyses (Fischl and
ale, 2000; Lerch et al., 2008a) are unbiased whole-brain-
ased methods used to study the pattern of neurodegen-
ration and neuro-anatomical correlates of HD. Although
hese methods are automated, there are numerous differ-
nces between research groups in the software used, the
rocessing steps and statistical models applied, and the
orrection of the resulting statistical parametric maps, all of
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219 207hich may affect overall results. A principled approach is
herefore mandatory.
In brief, VBM requires a series of automated image
re-processing steps, including segmenting images into
rey matter (GM), white matter (WM) and cerebrospinal
uid (CSF) compartments, spatially aligning (normalizing)
hese compartments into standard stereotactic space and
pplying appropriate smoothing for subsequent analysis at
roup level. A number of different analytical path specifi-
ations have been used and reported: some studies opti-
ize the normalization but not segmentation, some use a
tudy-specific template for normalization and these may be
hole brain templates or templates designed for the tissue
lasses under study. Some researchers introduce other
ew steps into the analytic path with varying degrees of a
riori justification (compare, e.g. Thieben et al., 2002;
einemann et al., 2005; Douaud et al., 2006).
Within the few published cortical thickness analyses in
D, there is variation in both the software and methodol-
gy applied. Rosas et al. (e.g. Rosas et al., 2008) use the
urface-based software package FreeSurfer (Fischl and
ale, 2000), which automatically extracts the inner and
uter cortical surfaces using deformable models, and cal-
ulates cortical thickness as the shortest distance between
he pial and WM surfaces (Fischl and Dale, 2000). By
ontrast, cortical thickness measurements in the YAC128
ouse-model study (see further below) use Laplace’s
quation to create streamlines between the inside and
utside cortical surfaces, with the length of streamline
iving the measurement of thickness (Lerch et al., 2008a).
opoulos et al. (2007) used the BRAINS2 family of soft-
are programs (Magnotta et al., 2002) to extract a model
epresenting the parametric center of the GM tissue class,
hich approximates the spatial center of the cortex. Here,
ortical depth is measured as the minimum distance be-
ween the 100% GM surface and the center of the cortex
i.e. 50%/50% GM/WM surface). These methodological
ifferences are likely to have some effect on results and
hould be considered when comparing studies of cortical
hickness.
There is a large amount of inconsistency in the spec-
fication of the covariates included in statistical models for
nalysis (O’Brien et al., 2006). VBM studies often, but notig. 1. The figure illustrates the impact of different smoothing kernels (ranging
hinning.lways, include age, gender, and total intracranial volume
TIV) as nuisance factors, since they can affect brain vol-
me independently of disease. VBM studies also tend to
djust for total GM volume. This approach allows for in-
estigation of region-specific patterns of atrophy and rela-
ive atrophy or preservation of tissue (Muhlau et al., 2007);
owever it is important that GM volume is not used as a
ubstitute for head size, particularly in studies of neurode-
eneration, as total as well as regional GM volume may
ary with disease severity and duration. Cortical thickness.
ortical thickness analyses tend to correct for age and
ender but not TIV. There appears to be no relationship
etween brain size and cortical thickness in mice (Lerch et
l., 2008a) but recent work indicates that the relative di-
ensions of sulcal depth with respect to cortical thickness
hange with head size in humans (Im et al., 2008).
Some smoothing is generally required to compensate
or small variation in individual anatomy during inter-sub-
ect registration, and to ensure that the data are normally
istributed (statistically stationary). The amount of smooth-
ng sensitizes analyses to a particular spatial scale of effect
Ridgway et al., 2008) which will affect interpretation of
esults; the detection of change in a structure is more
ensitive if the smoothing kernel approximates the size of
he structure. For VBM analyses, segments are smoothed
hrough convolution with a volumetric gaussian kernel.
ernel sizes in the HD literature range from full-width at
alf-maximum (FWHM) 4 mm (Barrios et al., 2007) to 12
m (Kipps et al., 2005). However, the majority of studies
o not justify their choice of smoothing kernel, for example,
y attempting to match the spatial extent to that of the
egenerative change expected (see Kassubek et al.,
004b for an example of selecting the smoothing kernel
ased on visual inspection of structural changes). In cor-
ical thickness analyses, smoothing is typically carried out
cross the cortical surface to follow the topology of the
ortex (Rosas et al., 2002, 2005, 2008; Lerch et al.,
008a). The amount of smoothing varies greatly in the few
ortical papers published, for example Rosas et al. (2005)
sed a 2D gaussian kernel of FWHM 29 mm but a 3D
ernel of FWHM 16 mm in earlier work. Fig. 1 shows the
ffects of varying a surface-based gaussian smoothing
ernel from FWHM 10–30 mm on the same dataset. As thefrom 10 to 30 mm) on the apparent distribution and severity of cortical
k
t
u
d
a
t
H
v
T
(
(
t
m
fi
w
k
a
s
s
m
i
H
b
e
i
H
2
g
s
t
a
I
H
c
e
r
a
o
(
S
T
s
t
d
o
m
r
2
e
o
t
c
s
G
r
t
l
b
N
m
a
p
d
t
fi
b
P
s
p
i
s
m
s
e
r
c
m
p
a
c
r
G
c
e
W
F
d
s
d
S. Klöppel et al. / Neuroscience 164 (2009) 205–219208ernel size increases, the area of significant differences
ends to increase. Therefore, differences between studies
sing different smoothing kernel types may not reflect true
isease-related differences in the cohorts studied. For ex-
mple, Lerch et al. (2008a) found an increase in cortical
hickness of the sensorimotor cortex in the YAC128 mouse
D model relative to wild-type mice at a stage representing
ery early stage HD/presymptomatic gene carriers (PSC).
his finding agrees with some results from human PSC
Paulsen et al., 2006b), but contradicts others; Rosas et al.
2005) found regionally-selective thinning and no areas of
hickening in their PSC cohort.
In summary, this section has illustrated a number of
ethodological issues which are likely to influence imaging
ndings. However, it is difficult to predict how each issue
ill affect the overall result. The effects of smoothing-
ernel size have been explored systematically (Jones et
l., 2005) but are likely to be dependent on the specific
tudy. In contrast, the effect of changing regressors in the
tatistical design or using different means for spatial nor-
alization is very difficult to predict. Such methodological
ssues need to be considered when trying to interpret the
D literature and to generalize results. Ideally, as has
een suggested recently (Nopoulos et al., 2007), research-
rs need to consolidate methods in order to produce find-
ngs that are replicable, robust, and truly representative of
D. Recently published sets of guidelines (Ridgway et al.,
008) could prove helpful in that respect. Such general
uidelines are preferable to very specific ones (e.g. a
pecific smoothing kernel or a specific set of covariates) as
heir choice will depend on the exact research question
nd dataset being investigated.
STRUCTURAL CORRELATES OF CLINICAL
FEATURES AND SUBJECT STRATIFICATION
n this section, we summarize recent structural MRI work in
D, as well as how these in vivo findings relate to the
linical features observed in disease. We also highlight
vidence that stratification based on e.g. number of CAG
epeats or clinical phenotype, yields distinct patterns of
trophy. Tables providing an excellent overview of previ-
usly published studies are provided in another review
Bohanna et al., 2008).
tructural MRI in HD
he most striking pathological changes in HD occur in the
triatum (Halliday et al., 1998; Gutekunst et al., 2002) and
here is a wealth of evidence that striatal atrophy can be
etected using MRI up to 23 years prior to predicted motor
nset and that striatal volume is negatively correlated with
otor and cognitive function and CAG repeat length (Har-
is et al., 1992, 1996, 1999; Aylward et al., 1994, 1996,
004; Rosas et al., 2001; Kassubek et al., 2004b; Paulsen
t al., 2006b; Fig. 2).
The contribution of cortical regions to the pathophysi-
logy of HD has been of increasing interest, since hunting-
in-protein aggregates have been found to concentrate in
ortical neurons to an even greater extent than in the ttriatum (Ferrante et al., 1997; Sapp et al., 1997;
utekunst et al., 1999). Extra-striatal atrophy has been
eported in early HD including WM loss in the absence of
otal brain volume or GM loss (Aylward et al., 1998; Beg-
inger et al., 2005). Others have reported reduced total
rain volume or GM loss (Rosas et al., 2003; Fennema-
otestine et al., 2004; Kassubek et al., 2004a,b).
Reduced cortical thickness has been found in early to
oderate HD, with a suggestion that the sensorimotor
reas are most severely affected and that atrophy
rogresses from posterior to anterior regions with longer
isease duration (Rosas et al., 2002, 2008). Of studies
aking a whole-brain rather than an ROI approach, most
nd evidence of bilateral caudate and putaminal atrophy in
oth early disease and in PSC (Thieben et al., 2002;
einemann et al., 2005). In contrast there is less consen-
us about extra-striatal atrophy; for example insular atro-
hy has been shown in PSC (Thieben et al., 2002), but not
n a study in early HD (Kassubek et al., 2004b). There are
imilarly variable results on the involvement of the thala-
us, amygdala, hypothalamus, and frontal areas (Kas-
ubek et al., 2004b, 2005; Peinemann et al., 2005; Douaud
t al., 2006; Muhlau et al., 2007). This could be an effect of
elatively small group sizes, different clinical stages or the
hoice of statistical thresholds. It should also be kept in
ind that increasing levels of degeneration can result in
roblems with image registration in areas not themselves
ffected by disease (e.g. an inward shift of the insular
ortex with shrinking striatal volume).
Abnormal brain volume has also been found in PSC. A
ecent study found evidence of reduced WM but normal
M volume in PSC approximately 11 years from predicted
linical onset (Paulsen et al., 2006b). In contrast, PSC
stimated at 23 years from onset had more grey and less
M than normal, in the absence of any increase in ven-
ig. 2. Example displays areas with decreased GM (P0.001) as
etected by VBM comparing early HD subjects to controls (see Kas-
ubek et al., 2005; for details on group characteristics and metho-
ology).ricular size or CSF volume, which led the authors to
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219 209ostulate that their result may represent a developmental
bnormality rather than a very early neurodegenerative
rocess (Paulsen et al., 2006b). Total brain volume was
ot significantly reduced although further work on the
ame cohort demonstrated morphological GM abnormali-
ies, including increased gyral surface area, thicker gyri,
nd thinner sulci (Nopoulos et al., 2007). Decreased WM
as been reported to correlate with years to onset in PSC,
hile the same study showed a non-significant reduction of
M (Ciarmiello et al., 2006). However, GM thinning in
egions across the cortex has also been reported in this
opulation (Rosas et al., 2005).
In summary, structural MRI studies in early HD tend to
upport the postmortem findings (Vonsattel and DiFiglia,
998; Gutekunst et al., 2002) of widespread generalized
trophy throughout the cortex, with disproportionate vol-
me loss in the striatum. Where both GM and WM are
easured, there is a suggestion that WM loss is relatively
reater or seen earlier in the course of the degeneration
see section on DWI). PSC have clear striatal atrophy and
here is evidence of WM loss but the involvement of corti-
al GM is less clear. There is considerable variation be-
ween studies both with regard to the extent of extra-
triatal atrophy and the point in the disease process at
hich loss in different regions starts to become significant.
n many cases these differences may be due to method-
logical differences or lack of statistical power caused by
he small or heterogeneous groups selected for study.
lternatively, they may reflect true heterogeneity in the
opulations sampled. Although it is clear that widespread
tructural loss occurs early in the disease, more work is
eeded to define the pattern, time course, severity, signif-
cance, and evolution of these changes more clearly, par-
icularly in the early PSC phase.
The majority of longitudinal structural MRI studies in
D have focused on the striatum and it is now well estab-
ished that striatal atrophy rates are increased prior to
nset of motor symptoms and that they may not be linearly
rogressive, at least in the pre-clinical stage. Atrophy rate
s also correlated with CAG repeat length (Aylward et al.,
997, 2000, 2004; Aylward, 2007). Other studies focusing
n the whole brain have reported a decrease in WM vol-
me in PSC over periods as short as 16 months
Ciarmiello et al., 2006), but others have reported atrophy
f subcortical GM but no WM changes in PSC subjects
ver a period of 2 years (Kipps et al., 2005). In clinically
anifest HD, there have been reports of no change over
8 months (Ciarmiello et al., 2006), increased whole-brain
trophy rates measured over 6 months (Henley et al.,
006), and a decrease in insula, cerebellum and some
egional cortical volumes over a 1-year period (Ruocco et
l., 2008). The specificity of the latter results may need
larification as subjects were aged from 4 to 73 years, but
esults were not adjusted for either age or head-size
Ruocco et al., 2008).
eural correlates of clinical performance in HD
number of imaging studies have confirmed the existence
f a relationship between striatal volumes and cognitive aeficits (Bamford et al., 1989; Starkstein et al., 1992;
randt et al., 1995; Harris et al., 1996). Measures of frontal
obe size correlate with memory and planning performance
Bamford et al., 1989, 1995; Backman et al., 1997) and
egions including the thalamus (Kassubek et al., 2005),
nsula (Peinemann et al., 2005), WM (Beglinger et al.,
005; Rosas et al., 2006), and widespread cortical regions
Rosas et al., 2005, 2008) are associated with cognitive
erformance in both PSC and early clinically manifest HD.
ost of these studies have focused on a few tests in a
pecific domain (executive function) although recently it
as also been shown that striatal and frontal regions are
ssociated with performance on emotion recognition (Hen-
enlotter et al., 2004; Kipps et al., 2007; Henley et al.,
008).
tratification of subjects for clinical trials
problem in HD research is the heterogeneity of subject
roups, making it hard to detect small differences in vari-
bles of interest or to track change over time. One solution
s to stratify subjects based on clinical characteristics, and
t has been demonstrated that such stratified groups do
how different patterns of atrophy. When stratified by CAG
epeat length, motor or cognitive score, subjects with
onger repeat lengths (or worse scores) show more exten-
ive atrophy, that also affects extra-striatal regions, than
hose with shorter repeat lengths (or better motor scores)
Kassubek et al., 2004b), when compared with controls.
SC subjects, when stratified by estimated time to clinical
nset, also demonstrate differences in the amount of stri-
tal, grey and WM atrophy that are time dependent
Paulsen et al., 2006a). More recently, there has been a
uggestion that patients showing more bradykinetic fea-
ures of HD show a different pattern of cortical thinning to
hose without these features (Rosas et al., 2008). How-
ver, in most analyses of this type small subgroups were
ompared with controls, rather than directly with each
ther. Therefore, more work is needed to validate MRI
ifferences and to determine whether they can be used to
tratify pre-clinical and symptomatic subjects so that more
omogeneous cohorts can be entered into clinical trials.
FUNCTIONAL MRI IN HD
ithin the past 5 years, fMRI has been increasingly used
o study basic sensory, emotional and cognitive processes
n HD. In this section we seek to update the reader on new
evelopments in fMRI research since the review recently
rovided by Bohanna et al.(2008) and address three main
uestions that arise from published fMRI findings in clinical
D and PSC.
oes evidence from fMRI suggest a distinct pattern
f neural dysfunction during cognitive processing
n HD?
ublished fMRI studies (see Bohanna et al., 2008 for
ables providing an overview of the main findings) have
hown that abnormal activation patterns including hyper-
nd hypo-activation in HD patients and PSC are not re-
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219210tricted to the striatum. The stage of the disease as well as
he clinical phenotype might contribute to data heteroge-
eity, and differential patterns of neural dysfunction during
ifferent stages of the illness still have to be determined in
arger patient cohorts. Taking these clinical limitations into
ccount, the extant fMRI data in clinical HD suggest a
omplex pattern of neural dysfunction during cognitive pro-
essing, including a widespread set of subcortical and
ortical regions which have been found to show abnormal
rain activation responses compared to healthy subjects.
hese findings, however, do not converge to define a
ingle functional biomarker of HD, but rather suggest a
ynamic pattern of neural dysfunction in clinical HD and
SC which possibly depend on task type, cognitive de-
and, task performance, or a combination of all three
ariables.
For instance, abnormal activation of the anterior cin-
ulate cortex in clinical HD has been shown during the
imon response conflict task (Georgiou-Karistianis et al.,
007), but not during processing by working memory (Wolf
t al., 2008c) or during implicit motor learning (Kim et al.,
004). These results suggest that the detection threshold
or aberrant neural responses in the cingulate cortex could
e task-dependent. Furthermore, although the majority of
MRI studies have so far demonstrated reduced task per-
ormance during cognitive processing in clinical HD (Kim et
l., 2004; Georgiou-Karistianis et al., 2007; Wolf et al.,
008c), the relationship between task performance and
rain dysfunction has to be determined, since both de-
reased brain activation (Wolf et al., 2008c) and increased
unctional connectivity (Thiruvady et al., 2007) in clinical
D have been discussed against the background of im-
aired task accuracy. Several authors have discussed cor-
ical hyperactivation shown by fMRI in terms of neural
compensation” (Paulsen et al., 2004; Georgiou-Karistianis
t al., 2007; Wolf et al., 2007; Zimbelman et al., 2007),
lthough the compensatory processes related to functional
bnormalities remains to be characterized in terms of a
ask-related mechanism. Indeed, increased brain activa-
ion in the presence of task-stimulation does not necessar-
ly have to mirror task-specific processes, and thus other
xplanations appear plausible, e.g. the possibility of ab-
ormally increased activation that interferes with brain ac-
ivation typically elicited by a given task. For instance, a
ositive correlation between the UHDRS motor score and
ctivation of right dorsal and left ventral premotor regions
as been reported in clinically affected patients with HD
hile performing a response conflict task (Georgiou-Karis-
ianis et al., 2007). The authors interpreted this relationship
s related to characteristics of the disease, and suggested
hat patients with more severe motor symptoms could
xhibit greater baseline motor region activity in order to
nhibit involuntary movements, while the alternative inter-
retation of a relationship between premotor activation and
ncreasing task difficulty needs further validation.
Moreover, the question is open whether brain activa-
ion abnormalities during cognitive performance as shown
n HD are qualitatively different from the pattern of neural
ysfunction observed in other basal ganglia disorders, e.g. Parkinson’s disease (PD) (Monchi et al., 2000; Lewis et al.,
003). For instance, reduced activation of the prefrontal
ortex and the putamen during working memory perfor-
ance has been reported in both patients with PD (Lewis
t al., 2003) and HD (Wolf et al., 2008c). Furthermore,
omewhat similar to fMRI findings in HD, patterns of both
ncreased and decreased brain activation have been pre-
iously reported in PD patients during executive process-
ng (Monchi et al., 2007). While the notion of a differential
ngagement of the caudate nucleus during distinct pro-
essing phases of a cognitive task (Monchi et al., 2006,
007) could partially explain divergent findings of in-
reased and reduced brain activation in HD and PSC, this
ypothesis clearly needs to be explicitly tested in HD pa-
ients and PSC.
Eventually, it is also unclear if increased brain activa-
ion in HD patients and PSC could also reflect increased
ortical “noise” and thus a loss of regional specialization
Rajah and D’Esposito, 2005), e.g. due to a generalized
opaminergic deficit, rather than reflecting circumscribed
eficits due to the disease or due to task-specific factors.
urthermore, the impact of GM volume changes and ab-
ormal neurovascular coupling on neural activation and
lood-oxygenation level dependent (BOLD) responses is
ot well-known yet, and could additionally lead to aberrant
OLD fluctuations associated with neurodegeneration
nd cerebrovascular dysregulation (Deckel et al., 1998;
eckel, 2001).
an functional connectivity analyses provide further
nsights into early pathophysiological processes in
SC and into disease-related brain dysfunction
uring the symptomatic period?
iven the association between striatal abnormalities and
ognitive performance in PSC (Backman et al., 1997; So-
omon et al., 2007), as well as anatomical evidence for
opographically organized reciprocal connections between
he striatum and neocortex (Middleton and Strick, 2000), it
as been suggested that dysfunction of corticostriatal cir-
uits may characterize pre-clinical stages of HD (Reading
t al., 2004; Feigin et al., 2006) before the onset of overt
rain atrophy and motor, psychiatric or cognitive distur-
ances.
It is unclear at present if regionally abnormal brain
ctivation during the presymptomatic period reflects aber-
ant corticostriatal pathways related to progressive subcor-
ical atrophy, or if a primarily cortical deficit independent of
he neurodegenerative process in the striatum could addi-
ionally account for findings of primarily cortical dysfunction
n PSC (Reading et al., 2005; Wolf et al., 2007). Although
t is neuroanatomically plausible that cortical regions show-
ng abnormal activation in PSC could reflect an early dis-
uption of corticostriatal networks, e.g. as a consequence
f impaired corticostriatal connectivity, recent evidence
uggests that aberrant connectivity of functionally related
etworks extends beyond corticostriatal decoupling. For
nstance, a lower expression of functional networks involv-
ng dissociable dorsolateral prefrontal circuits was found in
SC during working memory processing despite absent
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219 211ifferences in task performance compared to healthy con-
rols (Wolf et al., 2008a). By means of a model-free multi-
ariate analysis technique (independent component anal-
ses; ICA), two distinct temporally coherent networks
TCNs) (Calhoun et al., 2008a) were identified that were
ositively correlated with the delay period of a verbal work-
ng memory paradigm. These TCNs comprised cortical
nd subcortical regions specified by a distinct spatiotem-
oral pattern comprising frontostriatal and fronto-parietal
reas (Fig. 3). In PSC, decreased functional connectivity
as found in left lateral prefrontal and bilateral striatal
reas, as well as in left fronto-parietal regions compared to
ealthy controls. Interestingly, contributions of the lateral
refrontal cortex were not confined to frontostriatal path-
ig. 3. Positive TCN identified by means of ICA in healthy controls (g
emory task (Wolf and Walter, 2005; Wolf et al., 2008a). Top right: W
re-HD individuals versus healthy comparison subjects comprised the
nsula, the bilateral putamen and the right caudate. Bottom right: Wit
re-HD individuals versus healthy comparison subjects comprised the
l., 2008b). The 2nd level spatial maps are rendered on the anatomical temp
ricron/] (left) and SPM5 (right).ays, but were also detected in left lateralized fronto-
arietal networks with sparing of the striatum, suggesting
dditional cortical decoupling without involvement of sub-
ortical structures (Wolf et al., 2008a). It is yet an open
uestion however, whether impaired striatal transmission
an also explain the latter findings since multimodal imag-
ng data (e.g. PET and fMRI measures obtained in an
dentical PSC sample) are lacking at present.
Regionally increased activation of the anterior cingu-
ate cortex (Georgiou-Karistianis et al., 2007), as well as
isrupted functional connectivity between the anterior cin-
ulate and lateral prefrontal cortex has been shown in
linically affected subjects. The latter finding was associ-
ted with slower reaction times and more frequent errors
d pre-HD subjects (blue) during the delay period of a verbal working
redominantly frontostriatal TCN, areas with decreased connectivity in
tro- and dorsolateral prefrontal cortex, the left parietal lobule, the left
dominantly frontoparietal TCN, areas with decreased connectivity in
olateral prefrontal cortex and the left superior parietal cortex (Wolf etreen) an
ithin a p
left ven
hin a pre
left dorslates implemented in MRIcron [http://www.sph.sc.edu/comd/rorden/
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219212uring a Simon task (Thiruvady et al., 2007). These find-
ngs are suggestive of a functional decoupling between the
nterior cingulate and the lateral prefrontal cortex in HD
atients, which might partly account for the deterioration in
erformance. Increased cortical activation could mirror re-
ional compensatory processes as a result of this impaired
onnectivity (Thiruvady et al., 2007). In contrast to these
ndings, impaired brain activation in the absence of coin-
idental hyper-activation has been found during working
emory processing at intermediate and high levels of
ognitive processing (Wolf et al., 2007). One possible ex-
lanation for these findings is related to load-dependent
echanisms of frontostriatal function, which have been
epeatedly shown with fMRI in healthy subjects (Rypma
nd D’Esposito, 1999; Rypma et al., 1999; Wolf and
alter, 2005). With low task demands, brain activation
uring cognitive processing may be similar in HD patients
nd controls, or may augment as a consequence of in-
reased cognitive effort to optimize task performance.
iven the possible load-dependency of neural dysfunction
n clinical HD, parametric activation paradigms may be
ore suitable for assessment of gradual brain activation
nd related functional connectivity changes between cor-
ical regions and the striatum (Wolf et al., 2008b).
re functional brain activation changes in clinical HD
nd PSC subjects sensitive and reliable biomarkers
f neurodegeneration and disease progression?
he role of fMRI in tracking disease progression needs
urther evaluation at present. For instance, volumetric data
uggest a relative decrease of striatal GM in PSC (Kipps et
l., 2005) and cortical volume changes in HD patients over
ime (Ruocco et al., 2008) however longitudinal fMRI data
n both PSC and HD patients are lacking so far. Thus, it is
nclear at present if functional or volumetric data are
qually sensitive in the detection of early abnormalities in
SC and for tracking disease progression. Moreover, al-
hough inferences can be made using cross-sectional
ears to clinical onset data (Paulsen et al., 2004; Wolf et
l., 2007; Zimbelman et al., 2007; Saft et al., 2008), it is still
ot possible to determine the temporal dynamics of brain
ctivation changes starting from the very early symptom-
tic period to overtly manifest HD. In designing longitudinal
MRI studies of HD, certain clinical and methodological
ssues should be taken into account. First, phenotypic
ariability in HD could represent a potential confound,
hich may reduce the power of fMRI designs using cog-
itive paradigms. Moreover, although a number of studies
ave shown cognitive deficits in PSC subjects (Lawrence
t al., 1996; Snowden et al., 2002; Lemiere et al., 2004),
he variability in cognitive performance has also been em-
hasized (Lundervold and Reinvang, 1995). Cognitive im-
airment does not evolve uniformly in PSC, either over
ime or with respect to specific cognitive domains (Lemiere
t al., 2004), again suggesting a neurobiological and phe-
otypic variability which has to be taken into account in
uture longitudinal studies. Studies of multiple cognitive
omains (e.g. psychomotor speed, attention, memory and
xecutive function) in populations using short, robust cog- sitive activation paradigms may offer a unique opportunity
o validate a range of stimulation tasks. Those could be
sed in clinical HD exhibiting manifest cognitive impair-
ent and PSC individuals with subtle cognitive deficits
elow the clinical threshold and associated neural abnor-
alities in one or more cognitive domains. Second, prac-
ice and learning effects or other strategic factors inherent
n given cognitive tasks must be considered as they may
e responsible for substantial inter- and intra-individual
ifferences in cognitive capacity (Rypma and D’Esposito,
999; Rypma et al., 2002). Of note, inferring neural dys-
unction in pre-HD so far has been derived from group
ctivation maps, and there is no clear consensus at
resent how data from complex cognitive activation tasks
hould be treated at the individual level. Furthermore,
ethodological heterogeneity in analyzing fMRI data might
imit the comparability between studies to a certain extent.
hile both ROI-driven approaches and whole-brain anal-
ses have been employed, most studies relied on a priori
odels for the estimation of the hemodynamic response in
he context of task-induced stimulation blocks or events. In
his context, multivariate statistical analyses might yield
ore robust results than those obtained by a general linear
odel approach (Calhoun et al., 2008b). However, these
ncreasingly used analysis and modeling techniques for
MRI data clearly need further evaluation before being
mplemented in a clinical trial design.
DIFFUSION WEIGHTED IMAGING
his method measures the diffusion of water molecules,
hich is influenced by the fiber architecture of the WM. It
llows a voxel-by-voxel comparison of diffusion properties,
ostly fractional anisotropy (FA) and mean diffusivity
Beaulieu, 2002). It also permits the tracking of WM fiber
onnections between different regions of the brain (Mori et
l., 1999). A recent review (Bohanna et al., 2008) provides
n up-to-date overview of findings in HD. Most consistently
eported findings include increases in FA in the putamen
nd globus pallidum.
It is not straightforward to conclude a specific histolog-
cal correlate of such FA changes. FA is a measure of the
nisotropy of the diffusion and ranges from zero to 1. FA is
ighest (anisotropic diffusion) in the large fiber tracts such
s the cortico-spinal tract but lower where fibers from
ifferent directions are crossing or within the GM. It effec-
ively reflects the coherence of the WM. Studies on the
istological basis of FA changes usually focused on wal-
erian degeneration following traumatic brain injury or nor-
al brain development while very little is available on
eurodegenerative diseases (see Beaulieu, 2002; Mori
nd Zhang, 2006 for an overview). It is likely that a degen-
ration of fibers is associated with a decrease in FA.
owever, in regions where two fiber tracts are crossing a
egeneration of one fiber tract could lead to an increase in
A because the unaffected tract will now dominate and
ncrease WM coherence.
It should also be kept in mind that some of the ob-
erved FA changes (Rosas et al., 2006; Klöppel et al.,
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219 213008) could be the effect of misregistration of the images in
he presence of neurodegeneration. The WM/GM bound-
ry of the putamen could shift inwards. Areas where HD
ene carriers already show WM where the FA is relatively
igh would be compared to overlapping GM in controls.
his could lead to the observed FA increases in the puta-
en. A similar effect could explain reported decreases in
A in the external capsule. An inward shift of the insular
ortex could lead to areas where insular cortex in HD gene
arries could overlap with WM in controls. Given that the
hift of the boundary correlated with disease progression
o would FA values and progression. While this mecha-
ism could explain part of the data it certainly does not
xplain the complete picture. For example, no FA changes
ave been found in the caudate which should be equally
ffected by such misregistration. Interestingly, studies
ooking at mean diffusivity found changes also in the cau-
ate nucleus (Mascalchi et al., 2004; Seppi et al., 2006)
hich again argues for region specific degenerative
hanges.
As with fMRI, DWI can potentially be useful when
reparing or conducting clinical trials. Part of the substan-
ial clinical variability seen in HD may be a reflection of
ifferential involvement of fiber connections between cor-
ical and subcortical regions. For the case of eye-move-
ents, previous work has already shown a correlation
etween the individual pattern of fiber connections and the
evel of impairment in voluntary-guided saccades (Klöppel
t al., 2008). New implementations of fiber tracking have
een used to study whole circuits with encouraging repro-
ucibility (Draganski et al., 2008).
While few longitudinal data on DWI are available, en-
ouraging results on the exchangeability of DWI data be-
ween imaging centers has been presented (Landman et
l., 2007) (but see Ozturk et al., 2008).
It is still too early to decide on the usefulness of DWI to
ither understand the pathophysiology of HD or in the
reparation of treatment trials. Currently available data
uggest that it can help understanding WM changes al-
eady seen in T1-weighted images. When trying to sepa-
ate PSC from controls using either DWI or T1-weighted
maging, a better separation was achieved using DWI
Klöppel et al., 2008, 2009). A direct comparison is how-
ver made difficult as acquisition time was shorter for
1-weighted imaging and because only DWI-weighted
ata were acquired at a single imaging center. The com-
arison does however indicate substantial and disease
pecific changes already in the pre-symptomatic stage of
D to be detectable by DWI.
IMAGING: FROM MICE TO MAN
he identification of the genetic mutation causing HD has
ed to the development of several animal models of the
isease, which have provided fundamental insights into
ey aspects of disease pathogenesis (Sipione and Catta-
eo, 2001; Ramaswamy et al., 2007). Imaging in primates
as so far been limited to chemically generated HD models
Roitberg et al., 2002) which are unlikely to represent all cspects of the disease. While a transgenic HD model in
rimates has been reported very recently (Yang et al.,
008), most imaging research has focused on mouse mod-
ls (Ramaswamy et al., 2007) and this includes treatment
rials (Ferrante et al., 2002). Among other things, these
odels differ in the number of CAG repeats and whether
he genetic mutation replaces a wild-type copy of the hun-
ingtin gene (knock-in mice) or has been inserted into the
ouse genome, in addition to two normal copies of the
ouse HD gene (transgenic mice) (Ramaswamy et al.,
007). Although the knock-in mouse should represent a
etter model of HD in terms of genetics, even in the most
apidly progressing knock-in models end-stage disease
oes not occur until close to the mouse lifespan (2 years)
hich makes studies using these mice challenging
Wheeler et al., 2000; Lin et al., 2001). However, there is a
lear effect of repeat length as more CAG repeats cause
ubstantially more degeneration and clinical signs in both
ransgenic and knock-in mice (Van Raamsdonk et al.,
007).
Imaging studies have focused on the YAC and the
6/2 mouse models of HD (Ramaswamy et al., 2007).
otor symptoms and neuropathological changes in the
AC128 mouse with 128 CAG repeats resemble those of
umans. The phenotype of the YAC128 mouse includes a
yperactive phase at the age of 3 months but converts to
hypokinetic phenotype at 6 months compared to wild-
ype littermates (Slow et al., 2003). Interestingly, testing
atteries have found that cognitive decline precedes de-
ectable neuropathology as well as motor signs by the age
f 2 months (Van Raamsdonk et al., 2005). So far, the
arliest imaging studies in YAC128 mice have been car-
ied out at the later time point of 8 months (Lerch et al.,
008b). Imaging in mice is usually done with a far higher
eld strength than used in clinical work (7 T and higher in
ice vs. 1.5 or 3 T in humans) and scanning times of
everal hours (compared to around 10 min in humans). At
his stage of disease development, comparable to early
tage HD in humans, studies report evidence for an en-
argement of cortical structures including the right senso-
imotor cortex (Lerch et al., 2008b). The finding has been
epeated with analysis of cortical thickness (Lerch et al.,
008a). An increase of volume or cortical thickness was
lso found bilaterally in the cerebellum, while entorhinal
ortex and frontal cortex were enlarged on the left. The
tudy also found decreased volumes of the left inferior
olliculus and cerebral peduncle as well as right thalamus
nd striatum, frontal cortex, paraflocculus and anterior
ommissure (Lerch et al., 2008b).
Comparison of the findings of imaging studies of the
AC128 mouse model with those in humans reveals a
umber of similarities: most obviously, striatal degenera-
ion is consistently reported in humans (Thieben et al.,
002; Aylward et al., 2004; Kassubek et al., 2004b;
ouaud et al., 2006; Paulsen et al., 2006b). More interest-
ngly, mouse models provide new evidence for cortical
nlargement which, as reviewed, has also been suggested
n humans (Paulsen et al., 2006b). However, while in-
reased cortical volume has been suggested as the result
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219214f abnormal development, data from the YAC mouse show
negative correlation between decreasing striatal volume
nd increasing sensorimotor cortical thickness. Although
his could both be a primary effect of the disease, a com-
ensatory mechanism seems more likely.
Rosas and colleagues (2002, 2005, 2008) have con-
ucted a number of studies on cortical thickness in human
D subjects. While increases in cortical thickness and
olume were found in the 8-month-old YAC128 mouse
Lerch et al., 2008a), reflecting an early stage of HD,
ncreased thickness in humans was restricted to cingulate
reas, with thinning in sensorimotor cortex (Rosas et al.,
008).
Manual outlining and VBM have recently been used to
urther characterize 18-week-old R6/2 mice with 277 CAG
epeats (Sawiak et al., 2009a,b) and produced partially
ifferent results. The authors used VBM and located dif-
erences in a number of structures including cortex, cere-
ellum and striatum with gene status without characteriz-
ng the directionality. Manual outlining performed by the
roup found a significantly smaller cortex and striatum in
he R6/2 mice while these mice showed a larger globus
allidus. Studies in humans had indicated reduced volume
f this structure.
Those discrepancies could well be attributed to differ-
nces between mice and men in brain structure as well as
o differences in the underlying genetic model. They un-
erline current difficulties transferring results from mouse
odels to humans. Improved animal models, possibly in-
luding primates, are required, particularly as many drugs
re tested in the pre-clinical phase in such models before
roceeding to human phase 1 and 2 trials.
THE USEFULNESS OF IMAGING AS A
BIOMARKER
iomarkers in HD
biomarker is “a characteristic that is objectively mea-
ured and evaluated as an indicator of normal biological
rocesses, pathogenic processes, or pharmacological re-
ponses to a therapeutic intervention” (Biomarkers Defini-
ions Working Group, 2001). It can be used for diagnosis or
taging of disease, as an index of disease progression, or
o monitor clinical responses to an intervention. In the case
f HD, the genetic mutation is known and this therefore
erves as a diagnostic marker for the disease. A useful
arker for progression in HD needs to be sensitive to the
arly stages of the disease, be able to distinguish symp-
omatic benefit from slowing progression, be associated
ith a pathogenic process and clinical manifestation of the
isease, and be measurable objectively and reliably. In
ther words it must give a clear picture of part of the
isease process. It is then assumed that disease-modify-
ng treatments affecting the clinical characteristics and
athogenesis of a disease, leading to clinical benefit, will
imilarly effect changes in the biomarker thus leading to a
eliable marker of treatment efficacy. In addition, to be
seful in a typical clinical trial context, a biomarker needs to be tolerated, non-invasive, reliable and reproducible in
ulti-center settings.
Markers that can predict clinical benefits may poten-
ially also serve as surrogate endpoints. Currently typical
linical endpoints in HD are motor onset and death, but
rials in which these outcomes were used to assess drug
fficacy would take decades. A surrogate endpoint that
redicts motor onset (or death) could be used instead,
erhaps allowing therapeutic testing in the asymptomatic
ears prior to motor onset, and also reducing the length of
linical trials.
However, biomarkers may not always respond to treat-
ent in a predictable manner, as was seen in a recent
tudy for a potential treatment for Alzheimer’s disease
AD) in which whole-brain atrophy rates actually increased
n patients who responded to an antibody, although at the
ame time cognitive performance improved slightly (Fox et
l., 2005). This finding suggests that therapeutic effects
ay need to be evaluated using a number of different
iomarkers simultaneously, in order to provide a more
omprehensive picture of the relationships between chan-
es in different modalities.
maging as a biomarker
RI measures appear to have many advantages over
ther measures such as clinical or cognitive scores as a
otential biomarker. Brain volume is unaffected by subject
ood or tiredness. MRI can be analyzed blind to subject
dentity and gene status, and if necessary data collected
ver a number of sites can be analyzed by a single inves-
igator or fully automated and so measures can be objec-
ive and highly reproducible (Aylward, 2007; Stonnington
t al., 2008). However, brain volume can be affected by
edication or co-morbidity, as well as nutritional factors
uch as hydration (Duning et al., 2005) and so some inter-
nd intra-individual variability is likely to remain as a result
f factors such as these.
Technical issues such as scanner type and consis-
ency can also affect scan measurements. If scans are
cquired over a period of time it is important to ensure that
hanges in scanner calibration have not biased measure-
ents, although some changes (e.g. in voxel size) can be
orrected during post-processing (Whitwell et al., 2004). In
ddition, subjects need to remain still in the scanner for
dequate scan quality, which means that in a disease such
s HD some subjects will be unsuitable for scanning, and
tudies will tend to focus on PSC or early affected subjects.
ongitudinal studies may risk dropout from the more af-
ected subjects or only be representative of those with less
evere motor problems.
maging biomarkers in HD
n HD, caudate volume has been suggested as a potential
iomarker, because it can be measured objectively, is
ssociated with the major site of pathology in the disease,
nd predicts motor onset (Aylward, 2007). Whole-brain
trophy rate has also been suggested, as it is increased in
arly HD and measured using a robust, semi-automated
echnique (Henley et al., 2006). Others have pointed out
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S. Klöppel et al. / Neuroscience 164 (2009) 205–219 215he potential utility of techniques such as VBM (Douaud et
l., 2006) and cortical thickness measurements in provid-
ng indexes of change over time (Rosas et al., 2008). Only
ne study has used imaging in a treatment trial (Puri et al.,
002). While the study showed a treatment effect in both
maging and clinical ratings, it should be noted that the
umber of subjects in each treatment arm was very low
n4 and n3, respectively) and that imaging in late stage
D is very challenging.
Recently, multivariate methods combining information
rom a number of characteristic degenerative changes
ave caused increasing interest. While these methods are
sed primarily to detect subtle degeneration in PSC (Klöp-
el et al., 2009), they could prove useful to rate individual
evels of degenerative change before inclusion in a treat-
ent trial (Vemuri et al., 2008). Their usefulness as a
ensitive tool to detect disease progression remains to be
hown.
Bohanna et al. (2008) suggested multimodal imaging
ith the idea that structural MRI would be most sensitive to
low degenerative processes while fMRI could aid in mon-
toring pharmacodynamics. They also suggested a combi-
ation with DWI to test for microstructural changes (Bo-
anna et al., 2008). While this approach constitutes a
ethodological challenge, it could facilitate the interpreta-
ion of results. As described for the case of AD (Fox et al.,
005), increasing atrophy rates do not necessarily repre-
ent increasing neurodegeneration. Similarly, a “normal-
zation” of compensatory hyperactivation in HD found by
MRI could mean a true normalization, but could also mean
ontinuing degeneration.
Another issue, which is relevant to all potential markers
f HD, is that motor onset is itself subjective and does not
ully reflect the insidious onset of symptoms across multi-
le domains, which is now known to occur in HD. An ideal
urrogate endpoint should fully predict existing clinical out-
omes, but this will depend on how well the existing clinical
utcome measures reflect the disease in the first place, as
ell as the variability of the surrogate measure itself.
It is clear that more work is needed to measure change
n the natural course of HD, and to determine better indi-
ators of onset and progression of the disease. This is
articularly true for PSC and early affected subjects, those
ho are most likely to enter clinical trials and benefit from
isease-modifying treatments at an earlier stage in the
isease process. A number of relatively small treatment
rials using imaging as an outcome measure are curren-
ly being carried out. In addition, large multi-center stud-
es such as TRACK-HD (http://www.track-hd.net) and
REDICT-HD (Paulsen et al., 2008) are ongoing and are
ikely to provide new insights into both the pathophysiology
f HD and its measurement.
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